Tags

Type your tag names separated by a space and hit enter

Role of probiotics in the management of pouchitis.
Curr Pharm Des. 2014; 20(28):4561-4.CP

Abstract

The concept that the gut microbiota plays a major role in the development of pouchitis in ulcerative colitis patients after restorative proctocolectomy with ileal pouch-anal anastomosis, is widely accepted and supported by a widespread use of some antibiotics (metronidazole and/or ciprofloxacin, rifaximin) to treat this condition. A possible, safer therapeutic alternative is represented by probiotics. To date the controlled studies addressing the possible efficacy of probiotic agents in the treatment of active pouchitis are few and inconclusive. By contrast the prophylactic use of a probiotic mixture (VSL #3) appears to be able to prevent development of pouchitis. The most convincing results have been observed in the maintenance of remission, where the probiotic mixture has been found, in most of the performed controlled trials, significantly effective in preventing pouchitis recurrence.

Authors+Show Affiliations

Gastroenterology Unit, S.Raffaele University Hospital. Via Olgettina 60- Milano 20132, Italy. guslandi.mario@hsr.it.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24180410

Citation

Guslandi, Mario. "Role of Probiotics in the Management of Pouchitis." Current Pharmaceutical Design, vol. 20, no. 28, 2014, pp. 4561-4.
Guslandi M. Role of probiotics in the management of pouchitis. Curr Pharm Des. 2014;20(28):4561-4.
Guslandi, M. (2014). Role of probiotics in the management of pouchitis. Current Pharmaceutical Design, 20(28), 4561-4.
Guslandi M. Role of Probiotics in the Management of Pouchitis. Curr Pharm Des. 2014;20(28):4561-4. PubMed PMID: 24180410.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of probiotics in the management of pouchitis. A1 - Guslandi,Mario, PY - 2013/09/18/received PY - 2013/10/10/accepted PY - 2013/11/5/entrez PY - 2013/11/5/pubmed PY - 2015/2/24/medline SP - 4561 EP - 4 JF - Current pharmaceutical design JO - Curr. Pharm. Des. VL - 20 IS - 28 N2 - The concept that the gut microbiota plays a major role in the development of pouchitis in ulcerative colitis patients after restorative proctocolectomy with ileal pouch-anal anastomosis, is widely accepted and supported by a widespread use of some antibiotics (metronidazole and/or ciprofloxacin, rifaximin) to treat this condition. A possible, safer therapeutic alternative is represented by probiotics. To date the controlled studies addressing the possible efficacy of probiotic agents in the treatment of active pouchitis are few and inconclusive. By contrast the prophylactic use of a probiotic mixture (VSL #3) appears to be able to prevent development of pouchitis. The most convincing results have been observed in the maintenance of remission, where the probiotic mixture has been found, in most of the performed controlled trials, significantly effective in preventing pouchitis recurrence. SN - 1873-4286 UR - https://www.unboundmedicine.com/medline/citation/24180410/Role_of_probiotics_in_the_management_of_pouchitis_ L2 - http://www.eurekaselect.com/116493/article DB - PRIME DP - Unbound Medicine ER -